These results suggested that ICS II might produce protective effect against BCCAO-induced cognitive impairment by up-regulating the expressions of PPARα and PPARγ, not by retarding the decrease of the expressions of PPARα and PPARγ. The gene discussed is PPARA; the disease is Cognitive impairment.